Jean Francois Seitz

TL;DR: In patients with advanced hepatocellular carcinoma, median survival and the time to radiologic progression were nearly 3 months longer for patients treated with sorafenib than for those given placebo.

TL;DR: Data support MMR status assessment for patients being considered for FU therapy alone and consideration of MMR status in treatment decision making and patient stratification by MMR status may provide a more tailored approach to colon cancer adjuvant therapy.

TL;DR: Patients with high-risk resected colon cancer obtain benefit from FU-based therapy across subsets of age, sex, location, T stage, nodal status, and grade, which may improve patients' and physicians' understanding of the potential benefits of adjuvant therapy.

TL;DR: In this article, a pooled analysis of individual patient data from seven phase 3 randomized trials (involving 3351 patients) in which the effects of postoperative fluorouracil plus leucovorin (five trials) or fluorourocil plus levamisole (two trials) were compared with surgery alone in patients with stage II or III colon cancer was performed.

TL;DR: It is suggested that DFS after 3 years of median follow-up is an appropriate end point for adjuvant colon cancer clinical trials of fluorouracil-based regimens, although marginally significant DFS improvements may not translate into significant OS benefits.